January 3, 20221:48 PM UTCLast Updated 3 hours agoFuture of Health
Omicron evades immunity better than Delta, Danish study finds
- Omicron 2.7-3.7x more infectious than Delta among vaccinated
- Booster-vaccinated less likely to transmit coronavirus
- Risk of hospitalisation from Omicron half that of Delta
COPENHAGEN, Jan 3 (Reuters) – The Omicron coronavirus variant is better at circumventing vaccinated peoples’ immunity than the Delta variant, according to a Danish study published last week, helping explain why Omicron is spreading more rapidly.
Since the discovery of the heavily mutated Omicron variant in November, scientists have been racing to find out whether it causes less serious disease and why it appears more contagious than the previously dominating Delta variant.
A virus can be more transmissible due to a number of reasons, such as the time it lingers in the air, its ability to latch onto cells, or its evasion of the body’s immune system.
Register now for FREE unlimited access to Reuters.com
Investigating nearly 12,000 Danish households in mid-December, the scientists found that Omicron was 2.7 to 3.7 times more infectious than the Delta variant among vaccinated Danes.
The study, conducted by researchers at University of Copenhagen, Statistics Denmark and Statens Serum Institut (SSI), suggests the virus is mainly spreading more rapidly because it is better at evading immunity obtained from vaccines.
“Our findings confirm that the rapid spread of the Omicron (variant) primarily can be ascribed to the immune evasiveness rather than an inherent increase in the basic transmissibility,” the researchers said. The study has yet to be peer-reviewed.
Seventy-eight percent of Danes have been fully vaccinated, while nearly 48% of those have received a third “boosted” shot. More than eight out of ten Danes have received Pfizer-BioNTech’s vaccine.
The study also found that booster-vaccinated people are less likely to transmit the virus, regardless of the variant, than the unvaccinated.
While more transmissible, the Omicron variant does seem to induce less serious disease, SSI’s technical director, Tyra Grove Krause, told local media on Monday.
“While Omicron will still be able to put pressure on our healthcare system, everything indicates that it is milder than the Delta variant,” she said, adding the risk of being hospitalised with Omicron was half of that with Delta.
That echoes the results of some other studies into Omicron. read more
Out of a total of 93 people admitted to hospital due to COVID-19 from Omicron in late December, less than five were receiving intensive care, Danish data showed.
“This may be what is going to lift us out of the pandemic, so that this becomes the last wave of corona,” Krause said. read more
Our Standards: The Thomson Reuters Trust Principles.
More from Reuters
- Future of HealthAnalysis: China’s biotech sector comes of age with big licensing deals, global ambitionsSeptember 16, 2021
Sign up for our newsletter
Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
- Future of Health · 3:39 PM UTCU.S. FDA backs Pfizer’s COVID-19 booster shot for 12- to 15-year-oldsThe U.S. Food and Drug Administration has authorized the use of a third dose of the Pfizer and BioNTech COVID-19 vaccine for children aged between 12 and 15 years, and narrowed the time for all booster shots by a month to five months after the primary doses.
- Future of HealthOmicron hospitalisation risk around one third of Delta, UK analysis showsDecember 31, 2021
- Future of HealthSinovac COVID-19 shot with Pfizer booster less effective against Omicron – studyDecember 31, 2021
- Future of HealthBritain approves Pfizer’s antiviral COVID-19 pillDecember 31, 2021
- Future of HealthScientists to test high dexamethasone doses in severely ill COVID-19 patientsDecember 30, 2021
- About Reuters
- Reuters News Agency
- Brand Attribution Guidelines
- Reuters Leadership
- Reuters Fact Check
- Reuters Diversity Report
Information you can trust
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.
Thomson Reuters Products
- WestlawBuild the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
- OnesourceThe most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
- CheckpointThe industry leader for online information for tax, accounting and finance professionals.
- Refinitiv Workspace Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
- Refinitiv Data Catalogue Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
- Refinitiv World-CheckScreen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All rights reserved